NDAORALTABLET
Approved
Jun 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
WIDAPLIK (telmisartan, amlodipine and indapamide) by R-Pharm US is angiotensin 2 receptor antagonists [moa]. First approved in 2025.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WIDAPLIK is a fixed-dose combination tablet containing telmisartan (ARB), amlodipine (calcium channel blocker), and indapamide (thiazide diuretic) for oral administration. It is indicated for hypertension management in patients requiring multi-drug therapy. The combination works through complementary mechanisms: blocking angiotensin II receptors, dilating coronary and peripheral vessels, and promoting sodium and water excretion.
Growth11.2 years to LOE
Recent NDA approval (June 2025) positions WIDAPLIK in early growth phase with opportunity for field team expansion and market establishment activities.
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
WIDAPLIK offers career entry and growth opportunities within a newly launched, competitively unencumbered product in a high-volume therapeutic area. The 11+ year patent runway and growth-stage lifecycle provide career stability and potential for advancement as the brand establishes market presence.
Brand ManagerField Sales Representative
Worked on WIDAPLIK at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.